Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
November 02 2023 - 9:00AM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced the acceptance of a poster
presentation at the upcoming 65th American Society of Hematology
(ASH) Annual Meeting to be held in San Diego, CA from December
9-12, 2023.
Details of the poster presentation are as follows:
Title: Expansion, Persistence and Pharmacodynamic Profile
of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma
Delta T Cell Therapy, in Patients with Relapsed/Refractory
Aggressive B-Cell Non-Hodgkin’s Lymphoma Poster Number: 3478
Session Name: 704. Cellular Immunotherapies: Early Phase and
Investigational Therapies: Poster II Presenting Author:
Monica Moreno, Ph.D. Date/Time: Sunday, December 10, 2023,
from 6:00 - 8:00 p.m. PDT
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231102190660/en/
Adicet Bio., Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Sep 2024 to Oct 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Oct 2023 to Oct 2024